Study Description
This study is an uncontrolled, primary data collection-based observational study to be conducted as a central registration system, multicenter special drug-use results surveillance. As an all-case study, this study will collect all patients treated with Tabrecta in a specified post-marketing period. The observation period of each patient is up to 1 year (52 weeks)
Interventions
Tabrecta tablets
Eligibility Criteria
Inclusion Criteria:
All patients receiving Tabrecta for MET exon 14 skipping mutation-positive unresectable advanced/recurrent NSCLC during a specified post-marketing period
Exclusion Criteria:
-
Study Location
Novartis Investigative Site
Recruiting
Shimotsuga Gun,Tochigi,321-0293,Japan
Novartis Investigative Site
Recruiting
Sunto Gun,Shizuoka,411 8777,Japan
Novartis Investigative Site
Recruiting
Yokohama-city,Kanagawa,241-8515,Japan
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.